Navigation Links
Trigemina Presents at American Pain Society 32nd Annual Scientific Meeting
Date:5/9/2013

MORAGA, Calif., May 9, 2013 /PRNewswire/ -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, announced that David C. Yeomans , Ph.D., Chief Scientist and Founder, as well as the Director of Pain Research at Stanford University School of Medicine, gave a presentation at the American Pain Society (APS) 32nd Annual Scientific Meeting on May 8th, 2013, in New Orleans, Louisiana.   

Dr. Yeomans was selected by the APS to present data on Trigemina's lead product candidate, TI-001, an intranasal oxytocin pain therapy, during the Clinical and Basic Science Data Blitz event on Wednesday, May 8th, from 6 PM to 8 PM ET.  The blitz was composed of innovative and compelling presentation of new research, with presenters having five minutes to present and an additional five minutes to answer questions from the audience.

"The need to share and discuss new research in pain has become increasingly important, especially when considering the impact that prescription drug abuse has had on our country in recent years," said Dr. Yeomans. "The APS Data Blitz provides researchers and physicians with valuable information on emerging therapies, like TI-001, which may one day provide a safe, non-addictive and effective solution to people suffering from chronic pain."

TI-001 is currently being evaluated in a placebo-controlled, double-blind, randomized-withdrawal and enrollment enriched Phase II clinical study, titled TRIG-05, for efficacy, tolerability and safety in patients with chronic migraine. Promising preclinical and human pilot study results suggests TI-001 could be a safe, non-narcotic form of therapy for the effective relief of chronic migraine, a debilitating condition with few treatment options.  

About Trigemina
Trigemina is focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products. Trigemina's lead product candidate, TI-001, is a patented new application of oxytocin. TI-001 has shown promising results for use as a safe and effective therapy for all forms of chronic and subacute head pain.

For additional information, please visit www.trigemina.com

Contact:

The Ruth Group
Aaron Estrada (media)
aestrada@theruthgroup.com  
(646) 536-7028

Trigemina
Charles Yeomans
cyeomans@trigemina.com
(925) 377-0664


'/>"/>
SOURCE Trigemina, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Trigemina to Present at the 2013 BIO International Convention
2. Trigemina Receives ISP Approval of Clinical Study Protocol for TI-001 Phase 2 Trial
3. Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit
4. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
5. Assemblyman Levine Presents Resolution Recognizing Rare Disease Day at Capitol
6. Drogueria Americana, a Honduran Affiliate of GeneCell International, Presents to a Panel of More Than 100 Leading Dentist on Dental Pulp Stem Cells
7. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
8. Bluestar Silicones Presents Soft Silicone Advantages At Medical Design And Manufacturing (MD&M) West Show
9. Oracle’s Value Chain Summit San Francisco: Track Sponsor NexInfo presents more industry specific solutions
10. Fertility Associates of Memphis, World-Renowned Expert in Infertility, Presents Findings to European Conference
11. BCA Represents Independent Blood Centers at Phacilitate Cell & Gene Therapy Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... Ovation ... infertility as a disease, bringing new hope for prospective parents who are challenged ... meeting to back the World Health Organization’s designation in hopes of changing the ...
(Date:6/22/2017)... Lawrence, MA (PRWEB) , ... June 22, 2017 , ... ... completed ILVO validation. The AMPH test was determined to be appropriate as a screening ... for visual interpretation, on the Charm EZ system, and the Charm EZ Lite system. ...
(Date:6/20/2017)... ... June 20, 2017 , ... National ... well-versed leader with extensive assay development and biomarker expertise, as VP of Scientific ... Boston CRO specializing in bio-analytical assay development and sample testing services. The organization ...
(Date:6/19/2017)... ... June 19, 2017 , ... Tunnell Consulting has been solving the ... the biggest challenges faced by life sciences, biotech and pharmaceuticals companies today is in ... Kati Abraham , who is well known in the industry and brings significant high-level ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):